Uses of ouabain and ouabain-like molecules in apoptosis...

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S026000, C514S280000, C514S284000, C424S009100

Reexamination Certificate

active

06699676

ABSTRACT:

BACKGROUND OF THE INVENTION
The maintenance of the transmembrane gradient of monovalent cation (high [K
+
]
i
and low (Na
+
]
i
) is universal property of all nucleated cells and its dissipation is viewed as a hallmark of necrotic-type cell death (1,2). It was shown that a transient and moderate rise of intracellular Na
+
concentration in mitogen-treated cells is involved in rejoining DNA strand breaks preceeding DNA synthesis (3), whereas longterm inversion of the intracellular Na
+
/K
+
ratio blocks macromolecular synthesis and cell cycle progression in the majority of eukaryotic cells studied so far (4-7), including vascular smooth muscle cells (VSMC) (8,9). Much less is known about the role of the trans-membrane gradient of monovalent ions in the triggering and progression of programmed cell death (apoptosis).
Cell shrinkage is one of the initial morphological markers of apoptosis in all types of cells, particularly in VSMC (10). In immune system cells, apoptotic shrinkage is so impressive that the term “shrinkage-mediated necrosis” was originally proposed to describe this type of cell death (11), and the striking increase in density of shrunken cells was used to separate intact from apoptotic cells (12,13). In lymphocytes, the apoptotic cell volume decrease is caused by the loss of KCl (14) and a major organic osmolyte, taurine (15), due to the CD95 receptor-mediated activation of Cl

and K
+
channels and taurine outward transporter (for recent review, see (16)). However, the involvement of perturbation of intracellular ion composition and ionic strength of cytoplasm in the triggering and development of the apoptotic machinery remains unclear. Recently, it was shown that equimolar substitution of extracellular Na
+
by K
+
protects Jurkat cells from apoptosis induced by Fas-ligand receptors (14), suggesting that dissipation of K
+
gradients plays a role in the triggering of apoptosis in immune system cells. Here, we report that in contrast to Jurkat cells, inversion of the [Na
+
]
i
/[K
+
]
i
ratio blocks apoptosis of VSMC at a site upstream of caspase-3 independently on transmembrane gradient of monovalent cations and cell volume.
SUMMARY OF THE INVENTION
The present invention relates to methods, compositions and uses thereof for inhibiting apoptosis in a cell and/or increasing a cell's resistance to apoptosis. Preferred cells includes vascular smooth muscle cell (VSMC) and cell from the central nervous system.
More particularly, the invention provides a method for inhibiting apoptosis in a cell, comprising the step of increasing the cell's intracellular [Na
+
]/[K
+
] ratio.
The invention also provides a method for increasing a cell's resistance to apoptosis comprising the step of increasing the cell's intracellular [Na
+
]/[K
+
ratio.
The invention further provides methods for inhibiting caspase-3 biological activity in a cell, blocking induced chromatin cleavage in a cell, and preventing DNA laddering in a cell, each of these methods comprising the step of increasing the cell's intracellular [Na
+
]/[K
+
] ratio.
The invention also relates to the use of a compound or a composition that is capable of increasing intracellular [Na
+
]/[K
+
] ratio in a cell, for inhibiting apoptosis in a cell or for increasing the cell's resistance to apoptosis. The compound or the composition may also used for the preparation of a formulation for inhibiting apoptosis in a cell or for increasing a cell's resistance to apoptosis.
The invention further provides a pharmaceutical composition for inhibiting apoptosis in a cell or for increasing a cell's resistance to apoptosis, the composition comprising a compound that is capable of increasing a cell intracellular [Na
+
]/[K
+
] ratio and a pharmaceutically acceptable carrier or excipient.
The methods and compositions according to the present invention may be particularly useful for the prevention or treatment of numerous pathologies such as angina, myocardial infection, congestive heart failure, dilated cardiopathy, cardiopathy secondary to infarction, neurodegenerative disorder, including dementia and alzheimer.


REFERENCES:
patent: 3843628 (1974-10-01), Minato
patent: 4020159 (1977-04-01), Herrmann
patent: 4175078 (1979-11-01), Makarevich et al.
patent: 5153178 (1992-10-01), Maroko
patent: 5602105 (1997-02-01), Karsanov et al.
patent: 5695944 (1997-12-01), Croce et al.
patent: WO 9405305 (1994-03-01), None
Olej et al. (Bioscience Reports (1998) 18(1): 1-7).*
Xiao et al. (J. of Neuroscience (2002) 22(4): 1350-1362).*
Hardman et al. (The Pharmacological Basis of Therapuetics (1996) pp. 810-813).*
Djuricic et al. (Biochemical Society Transactions (1996) 24(4) 612S).*
Pchejetski et al. (Biochemical and Biophysical research Communications (2003) 301: 735-744.*
Bogdan Djuricic et al., Inhibiting of (NA,K)ATPASE in Thymocytes Reduces Apoptosis Induced by Microtubule-Disrupting Agents, vol. 24, No. 4, 1996, p. 612S, XP-001004750.
Bogdan Djuricic et al., “Apoptocic Thymocytes Change Appearance if Ionic Pump is Inhibited”, vol. 4, No. 14, 1998, pp. 815-816, XP-002174776/
Foey A.D. et al., “Dysfunctional NA/K-ATPASE Activity in Rheumatoid Synovial Lining Cells Results in a Defect in FAS-Mediated Apoptosis”, vol. 39, No. 9, 1996, pp. S132, XP-001004746.
Goodman-Gilman A. “The pharmacological basis of therapeutics” 1985, Macmillan Publ. Company, 7th Ed.,.
Francis, J. Haddy, “Potassium Effects on Contraction in Arterial Smooth Muscle Mediated by NA+, K+-ATPASE”, vol. 42, No. 2, 1983, pp. 239-245, XP-001004735.
Chemical Abstracts Service, Columbus, Ohio, SU, AN=1997;400150, XP-002174778.
Jutta Urenjak et al., “Pharmacological Modulation of Voltage-Gated Na+ Channels: A Rational and Effective Strategy Against Ischemic Brain Damage”, vol. 48, No. 1, 1996, pp. 21-67, XP-001004731.
Sergei N. Orlov et al., “Inversion of the Intracellular NA+/K+ Ratio Blocks Apoptosis in Vascular Smooth Muscle at a Site Upstream of Caspase-3”, Journal of Biological Chemistry, American Society of Biiological Chemists, Baltimore, MD, US, vol. 274, No. 23, 1999, pp. 16545-16552, XP-000993597.
Isaev N.K. et al., “Inhibition of NA+, K+-ATPASE Activity in Cultured Rat Cerebellar Granule Cells Prevent the Onset of Apoptosis Induced by Low Potassium”, Neuroscience Letters, Limerick, IE, vol. 283, No. 1, 2000, pp. 41-44, XP-001004641.
Database Medline, STN AN=2000094461, XP-002174779 & Parmley: “Surviving heart failure: Robert L. Frye lecture”, Mayo Clin. Proc., vol. 75, No. 1, 2000, pp. 111-118.
Sergei N. Orlov et al., “Inversion of the Intracellular NA+/K+ Ratio Blocks Apoptosis in Vascular Smooth Muscle Cells by Induction of RNA Synthesis”, Hypertension, vol. 35, No. 5, 2000, pp. 1062-1068, XP-001004747.
Robert J. Mark et al., “Amyloid &bgr;-Peptide Impairs Ion-Motive ATPase Activities: Evidence for a Role in Loss of Neuronal CA2+ Homeostasis and Cell Death”, Journal of neuruscience, vol. 15, No. 9, 1995, pp. 6239-6249, XP-001004822.
Marklund L. et al., “K+-Efflux Modulation of Cisplatin-Induced Apoptosis and Cytotoxicity to Cultured Mesothelioma Cells”, Investigative Ophthalmology & Visual Science, Association for Research in Vision and, US, vol. 38, No. 4, 1999, p. S109, XP-001006189.
Orlov SN, Thorin-Trescases N, Kotelevtsev SV, Tremblay J, Hamet P: Inversion of the Intracellular Na+/K+ratio blocks apoptosis In Vascular smooth muscle at a site upstream of caspase-3.J. Biol. Chem. 1999, 274:16545-16552.
Orlov SN, Taurin S, Thorin-Trescases N, Dulin NO, Tremblay J, Hamet P: Invasion of the Intracellular Na+/K+ratio blocks apoptosis in vascular smooth muscle cells by induction of RNA synthesis.Hypertension2000, 35:1062-1068.
Orlov SN, Li J-M, Tremblay, J, Hamet P: Genes of Intracellular calcium metabolism a

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Uses of ouabain and ouabain-like molecules in apoptosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Uses of ouabain and ouabain-like molecules in apoptosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Uses of ouabain and ouabain-like molecules in apoptosis... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3237476

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.